NCT06563804
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06563804
Title A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Servier Bio-Innovation LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | FRA | FIN | DEU | AUS

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
The University of Kansas Fairway Kansas 66205 United States Details
START Midwest Grand Rapids Michigan 49546 United States Details
Memorial Sloan Kettering New York New York 10065 United States Details
Fred Hutch Cancer Center Seattle Washington 98109 United States Details
Peter MacCallum Cancer Centre Melbourne 3000 Australia Details
Prince of Wales Hospital Randwick 2031 Australia Details
Helsinki University Hospital - Comprehensive Cancer Center Helsinki 00029 Finland Details
Institut Paoli Calmette Marseille 13009 France Details
Chu de Nice - Hôpital L'archet 1 Nice 062000 France Details
CHU de Bordeaux - Hopital du Haut Levêque Pessac 33604 France Details
Institut Gustave Roussy Villejuif 94800 France Details
Klinikum rechts der Isar der TU München München 81675 Germany Details
Universitätsklinikum Ulm Ulm 89081 Germany Details
Sapporo Hokuyu Hospital Hokkaido 003-0006 Japan Details
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo 113-8677 Japan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field